Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Safety Data Keeps Momenta/Sandoz’ Generic Lovenox In Play With FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

Response to immunogenicity concern could boost chances for FDA approval next year.

You may also be interested in...



Sanofi Sues FDA, Claiming Agency Exceeded Its Authority In Approving Enoxaparin

Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.

Sanofi Sues FDA, Claiming Agency Exceeded Its Authority In Approving Enoxaparin

Company claims the agency approved the generic although the innovator drug had not been fully characterized, but odds are against a Sanofi win in court.

The Year Ahead For Generic Drugs: The Calm Before The Storm

Several blockbuster drugs will face generic competition for the first time in 2010, but overall the year marks a reprieve for brand drug makers, one last chance to grip the ledge before tumbling over the patent cliff in 2011

Related Content

Topics

UsernamePublicRestriction

Register

PS067084

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel